Skip to main content
Ian Benjamin Gaddie on Muck Rack

Ian Benjamin Gaddie

As seen in: MDPI, Dove Medical Press, Texas Medical Center
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ian Benjamin

Contact Ian Benjamin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Effects of Lotilaner Ophthalmic Solution, 0.25%, on Demodex Blephariti

|
By Preeya K. Gupta, Ian Benjamin Gaddie, Mitchell C. Shultz, Patrick Vollmer
| Dove Medical Press
Introduction Meibomian gland disease is a common eye condition characterized by a chronic, diffuse abnormality of the meibomian glands, terminal-duct obstruction, and/or qualitative/quantitative variations in glandular secretion.1 Meibomian gland disease is the leading cause of the most common form of ocular surface disease, evaporative dry eye.
Open in Who Shared Issue with article?

"Delphi Panel Consensus Regarding Current Clinical Practice Management " by Marjan Farid, Brandon D Ayres et al.

|
By Marjan Farid, Brandon D. Ayres, Eric D. Donnenfeld, Ian Benjamin Gaddie
| Texas Medical Center
PURPOSE: To obtain consensus on Demodex blepharitis (DB) treatment using a modified Delphi panel process. METHODS: Literature search identified gaps in knowledge surrounding treatment of DB. Twelve ocular surface disease experts comprised the Demodex Expert Panel on Treatment and Eyelid Health (DEPTH). They completed a live roundtable discussion in addition to 3 surveys consisting of scaled, open-ended, true/false, and multiple-choice questions pertaining to the treatment of DB.
Open in Who Shared Issue with article?

Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis

|
By Pinakin Gunvant Davey, Marjan Farid, Paul Karpecki, Ian Benjamin Gaddie
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared View Duplicates (177) Issue with article?
See all 3 articles